Table 2

Peripheral blood urease specific IgG and IgA antibody secreting cells (ASC) by treatment group

Antiurease IgG secreting cells positive/total volunteers*Antiurease IgG peak ASC median† (range) [day to peak]Antiurease IgA secreting cells positive/total volunteers*Antiurease IgA peak ASC median† (range) [day to peak]
*Positive status defined as ≥15 urease specific ASC/106 peripheral blood lymphocytes. †Highest count of urease specific ASC/106 peripheral blood lymphocytes between day 7 and day 73. Positive results only.
Group 1: Soluble urease, no LT1/680 [73]1/630 [73]
Group 2: Soluble urease, 0.1 μg LT1/6129 [73]2/635 (30–39) [69]
Group 3: Soluble urease, 0.5 μg LT1/6130 [64]1/6146 [64]
Group 4: Soluble urease, 2.5 μg LT3/6110 (40–139) [36]1/6150 [36]
Group 5: Urease capsule, no LT1/6800 [64]1/6299 [64]
Group 6: Urease capsule, 0.1 μg LT1/670 [64]1/6100 [64]
Group 7: Urease capsule, 2.5 μg LT2/640 (40–40) [73]1/616 [44]